灵康药业
(603669)
| 流通市值：29.93亿 | | | 总市值：29.93亿 |
| 流通股本：7.21亿 | | | 总股本：7.21亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 296,100,557.45 | 343,418,554.46 | 474,874,066.61 | 428,602,617.49 |
| 应收票据及应收账款 | 55,561,661.7 | 64,710,631.77 | 64,832,402.31 | 68,462,366.72 |
| 应收账款 | 55,561,661.7 | 64,710,631.77 | 64,832,402.31 | 68,462,366.72 |
| 应收款项融资 | - | 894,240 | 298,080 | 602,784 |
| 预付款项 | 7,862,960.7 | 5,678,693.9 | 8,793,723.89 | 11,844,880.38 |
| 其他应收款合计 | 8,242,811.6 | 2,178,554.22 | 3,057,003.83 | 2,517,903.21 |
| 存货 | 58,465,779.3 | 56,768,282.16 | 68,505,161.89 | 49,046,150.44 |
| 其他流动资产 | 15,866,194.04 | 17,293,965.41 | 16,294,064.18 | 15,232,582.49 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 746,729,106.24 | 881,533,254.03 | 1,065,423,609.28 | 1,055,323,397.55 |
| 非流动资产: | | | | |
| 长期股权投资 | 37,392,314.09 | 40,874,881.63 | 43,029,582.76 | 44,331,837.32 |
| 其他权益工具投资 | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 |
| 投资性房地产 | 16,194,714.63 | 6,606,365.29 | 6,747,569.06 | 6,888,776.13 |
| 固定资产 | 259,754,505.22 | 275,357,994.03 | 277,221,454.34 | 286,293,019.7 |
| 在建工程 | 226,313,215.9 | 220,058,384.57 | 209,558,350.64 | 201,374,870.52 |
| 使用权资产 | 9,229,257.13 | 9,928,665.46 | 1,556,556.79 | 1,807,622.71 |
| 无形资产 | 106,624,944.69 | 108,435,835.2 | 110,591,496.05 | 112,286,477.09 |
| 长期待摊费用 | 16,376,046.01 | 17,147,244.75 | 17,265,644.06 | 18,145,393.21 |
| 递延所得税资产 | 2,191,247.9 | 2,198,900.92 | 242,434.04 | 194,093.65 |
| 其他非流动资产 | 2,359,825 | 2,418,600 | 11,389,923.9 | 11,075,823.9 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 736,436,070.57 | 743,026,871.85 | 737,603,011.64 | 742,397,914.23 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,483,165,176.81 | 1,624,560,125.88 | 1,803,026,620.92 | 1,797,721,311.78 |
| 流动负债: | | | | |
| 短期借款 | 17,360,718.34 | 117,411,134.98 | 217,454,059.33 | 217,094,820.08 |
| 应付票据及应付账款 | 72,439,516.49 | 95,290,443.47 | 85,235,145.34 | 66,137,869.12 |
| 其中：应付票据 | 20,484,647.05 | 39,876,263.43 | 31,992,716.02 | 32,669,668.78 |
| 应付账款 | 51,954,869.44 | 55,414,180.04 | 53,242,429.32 | 33,468,200.34 |
| 预收款项 | 282,329.1 | 169,002.37 | 352,012.75 | 168,731.34 |
| 合同负债 | 8,044,539.71 | 10,310,811.79 | 12,518,864.39 | 8,200,493.84 |
| 应付职工薪酬 | 3,153,600.29 | 8,756,413.27 | 2,964,408.01 | 3,276,413.1 |
| 应交税费 | 1,025,346.5 | 2,287,091.7 | 3,211,152.25 | 2,515,030.79 |
| 其他应付款合计 | 3,969,895.34 | 3,216,968.51 | 3,606,646.11 | 3,172,734.92 |
| 一年内到期的非流动负债 | 2,837,532.4 | 3,015,839.04 | 1,049,495.41 | 1,025,658.77 |
| 其他流动负债 | 2,056,003.31 | 2,652,739.97 | 2,073,884.07 | 2,134,920.46 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 111,169,481.48 | 243,110,445.1 | 328,465,667.66 | 303,726,672.42 |
| 非流动负债: | | | | |
| 应付债券 | 447,815,132.34 | 439,342,300.23 | 436,356,886.13 | 428,411,380.49 |
| 租赁负债 | 5,843,096.39 | 5,843,096.39 | 261,904.14 | 520,849.17 |
| 递延收益 | 2,722,364.56 | 2,804,035.47 | 2,892,849.71 | 3,291,663.95 |
| 递延所得税负债 | 2,266,683.22 | 2,418,101.2 | 232,895.41 | 93,164.39 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 458,647,276.51 | 450,407,533.29 | 439,744,535.39 | 432,317,058 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 569,816,757.99 | 693,517,978.39 | 768,210,203.05 | 736,043,730.42 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 721,238,653 | 721,238,653 | 721,238,536 | 721,238,536 |
| 其他权益工具 | 94,091,292.74 | 94,091,292.74 | 94,091,498.25 | 94,091,498.25 |
| 资本公积 | 255,639,079.79 | 255,639,079.79 | 255,638,009.49 | 255,638,009.49 |
| 减:库存股 | 110,019,822.2 | 108,367,599.67 | 60,009,646.36 | 60,009,646.36 |
| 盈余公积 | 144,362,187.9 | 144,362,187.9 | 144,362,187.9 | 144,362,187.9 |
| 未分配利润 | -191,962,972.41 | -175,921,466.27 | -120,504,167.41 | -93,643,003.92 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 913,348,418.82 | 931,042,147.49 | 1,034,816,417.87 | 1,061,677,581.36 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 913,348,418.82 | 931,042,147.49 | 1,034,816,417.87 | 1,061,677,581.36 |
| 负债和股东权益合计 | 1,483,165,176.81 | 1,624,560,125.88 | 1,803,026,620.92 | 1,797,721,311.78 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-21 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |